Clinical trial
A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
NCT07133425
Study timeline
Study start (actual)2025-11-06Date precision: day
Registry last updated2026-08-20
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-Small Cell Lung Cancerunresolved
ICI-refractoryunresolved
Interventions
SAR445877DRUG
Sponsors & collaborators
M.D. Anderson Cancer Centerlead sponsor
Sanoficollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07133425 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.